Last reviewed · How we verify
NCT07531121
ctDNA for Risk Stratification in Melanoma
trial in Melanoma (Skin Cancer) in 296 participants. Participants enrolled and being followed up; not accepting new ones.
20 May 2025
Quick facts
| Lead sponsor | Herlev and Gentofte Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 296 |
| Start date | 10 September 2021 |
| Primary completion | 20 May 2025 |
| Estimated completion | 3 May 2026 |
| Sites | 1 location across Denmark |
Conditions studied
- Melanoma (Skin Cancer) — all drugs for Melanoma (Skin Cancer) →
Sponsor
Herlev and Gentofte Hospital
Who can join
18 and older, any sex, with Melanoma (Skin Cancer). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study examines circulating tumor DNA (ctDNA) as a biomarker in patients with primary melanoma, prior to surgical excision. The hypothesis is that ctDNA may be detectable in pre-operative blood samples from patients with high-risk primary melanoma, potentially providing a baseline measurement for future disease monitoring.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07531121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma (Skin Cancer)
Currently open trials in the same condition.
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07287917 — Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07349303 — Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma · Phase 2 · recruiting
- NCT07376707 — A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic S · Phase 1 · recruiting
Other Herlev and Gentofte Hospital trials
Trials by the same sponsor.
- NCT07493590 — CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction · not yet recruiting
- NCT07321964 — The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fi · NA · recruiting
- NCT06706661 — Implementation of Nutritional Efforts on Discharged Older Patients · NA · recruiting
- NCT06618417 — Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with · NA · recruiting
- NCT06642272 — A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Hea · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07531121 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Herlev and Gentofte Hospital
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07531121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing